INT100220

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2001
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 13
Total Number 17
Disease Relevance 6.37
Pain Relevance 4.93

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Src) enzyme binding (Src) response to stress (Src)
cytoplasm (Src) cytosol (Src) cell proliferation (Src)
Anatomy Link Frequency
neurons 1
epithelial cell 1
Src (Rattus norvegicus)
Pain Link Frequency Relevance Heat
intrathecal 50 99.62 Very High Very High Very High
Opioid 1 99.40 Very High Very High Very High
5HT 90 99.34 Very High Very High Very High
Glutamate 23 98.52 Very High Very High Very High
opiate 1 97.88 Very High Very High Very High
cINOD 7 96.86 Very High Very High Very High
nMDA receptor 131 96.12 Very High Very High Very High
Dorsal horn neuron 24 96.12 Very High Very High Very High
opioid receptor 11 94.72 High High
MU agonist 1 93.64 High High
Disease Link Frequency Relevance Heat
Stress 6 99.64 Very High Very High Very High
Metastasis 8 99.32 Very High Very High Very High
Myeloid Leukemia 4 99.06 Very High Very High Very High
Chronic Myeloid Leukemia 4 98.96 Very High Very High Very High
Cancer 26 98.72 Very High Very High Very High
Constipation 1 98.72 Very High Very High Very High
Bordatella Infection 1 98.58 Very High Very High Very High
Adhesions 6 98.16 Very High Very High Very High
Disease 22 97.84 Very High Very High Very High
Breast Cancer 8 97.56 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Inhibition of calcium calmodulin-dependent kinase (CaMK) has no effect, but pERK is reduced by inhibition of the tyrosine kinase Src.
Negative_regulation (inhibition) of tyrosine kinase Src
1) Confidence 0.41 Published 2004 Journal J. Neurosci. Section Abstract Doc Link 15385614 Disease Relevance 0 Pain Relevance 1.02
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Negative_regulation (inhibition) of SRC associated with cancer, breast cancer and metastasis
2) Confidence 0.34 Published 2010 Journal Cancer Treat. Rev. Section Title Doc Link 20015594 Disease Relevance 1.28 Pain Relevance 0.09
Data arising from ongoing and future clinical trials will confirm whether SRC inhibitors provide clinical benefits for patients with advanced disease.
Spec (whether) Negative_regulation (inhibitors) of SRC associated with disease
3) Confidence 0.34 Published 2010 Journal Cancer Treat. Rev. Section Abstract Doc Link 20015594 Disease Relevance 1.27 Pain Relevance 0.06
This could be prevented by intrathecal administration of inhibitors of the signaling kinases Src and PKC and of group I metabotropic glutamate and NK1 receptors, revealing that in this model NR2B could be modulated by glutamatergic and tachykinin nociceptive transmission, leading to hyperalgesia.
Negative_regulation (inhibitors) of Src associated with nociception, hyperalgesia, glutamate and intrathecal
4) Confidence 0.28 Published 2008 Journal Neuroscience Section Body Doc Link PMC2568875 Disease Relevance 0.34 Pain Relevance 0.64
Pertussis toxin has no effect on the level of STAT5A phosphorylation, while the Src inhibitor PP1 abolishes opioid-dependent STAT5A phosphorylation.
Negative_regulation (inhibitor) of Src associated with bordatella infection and opioid
5) Confidence 0.27 Published 2005 Journal J. Neurochem. Section Abstract Doc Link 15857395 Disease Relevance 0.10 Pain Relevance 0.61
PDGF-BB treatment of hippocampal slices enhanced the phosphorylation of both the tyrosine 416 (associated with increased Src activity) and tyrosine 527 (associated with decreased Src activity (Figure 2C) [32,33].
Negative_regulation (decreased) of Src
6) Confidence 0.24 Published 2008 Journal Mol Brain Section Body Doc Link PMC2651131 Disease Relevance 0 Pain Relevance 0
They also showed that in HEK293T cells mutation of the Src-binding site on EphB2 or expression of a dominant negative of Fyn (inhibiting Src family kinases) disabled the phosphorylation of NR2B effect of ephrinB2 and the potentiation of NMDA receptor activity.
Negative_regulation (inhibiting) of Src associated with nmda receptor
7) Confidence 0.21 Published 2008 Journal Neuroscience Section Body Doc Link PMC2568875 Disease Relevance 0.22 Pain Relevance 0.31
Administration of PP2, which inhibits the Src family of protein tyrosine kinases, prior to administration of ephrinB2, prevented the increase in NR2B tyrosine phosphorylation (Fig. 1A lane 3 vs. lane 1 and 2).
Negative_regulation (inhibits) of Src
8) Confidence 0.21 Published 2008 Journal Neuroscience Section Body Doc Link PMC2568875 Disease Relevance 0.13 Pain Relevance 0.23
Src inhibitor PP2 also prolonged ERK stimulation by DPDPE.
Negative_regulation (inhibitor) of Src
9) Confidence 0.09 Published 2005 Journal J. Biol. Chem. Section Abstract Doc Link 15632168 Disease Relevance 0 Pain Relevance 0.31
There are a number of disclosures of Src or Src family inhibitors as anticancer agents that have or are likely to have Lck inhibitory activity.
Negative_regulation (disclosures) of Src
10) Confidence 0.09 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.50 Pain Relevance 0.20
Compound 23, a close structural analog of dasatinib (BMS-354825), a marketed kinase inhibitor drug for the treatment of chronic myelogenous leukemia (CML), is a potent, selective, and ATP-competitive inhibitor of Lck and other Src family kinases (IC50?
Negative_regulation (inhibitor) of Src associated with myeloid leukemia and chronic myeloid leukemia
11) Confidence 0.09 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.64 Pain Relevance 0.08
Compound 18 (racemic) is reported to be a potent inhibitor of Src (IC50?
Negative_regulation (inhibitor) of Src
12) Confidence 0.09 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.26 Pain Relevance 0.04
There are a number of disclosures of Src or Src family inhibitors as anticancer agents that have or are likely to have Lck inhibitory activity.
Negative_regulation (disclosures) of Src
13) Confidence 0.09 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.50 Pain Relevance 0.20
It happens to also indirectly reduce Src activity.
Negative_regulation (reduce) of Src
14) Confidence 0.08 Published 2009 Journal J. Neurooncol. Section Abstract Doc Link 19322519 Disease Relevance 0.39 Pain Relevance 0.10
-Me-5HT in PFC neurons treated with the Src kinase inhibitor, PP2.
Negative_regulation (inhibitor) of Src in neurons associated with 5ht
15) Confidence 0.06 Published 2008 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2427346 Disease Relevance 0 Pain Relevance 0.26
m, 3 min) in the absence or presence of the Src kinase inhibitor PP2 or its inactive homolog PP3 (both 10 ?
Negative_regulation (inhibitor) of Src
16) Confidence 0.06 Published 2008 Journal The Journal of Biological Chemistry Section Body Doc Link PMC2427346 Disease Relevance 0 Pain Relevance 0.21
Using a wounded gastric epithelial cell monolayer model, we demonstrated that NSAIDs reduce both basal and epidermal growth factor (EGF)-induced re-epithelialization, and that this action involves disruption of actin stress fiber formation, reduced c-Src activity, decreased phosphorylation of focal adhesion kinase (FAK), tensin and their cellular re-distribution.
Negative_regulation (reduced) of Src in epithelial cell associated with stress, cinod and adhesions
17) Confidence 0.04 Published 2001 Journal Life Sci. Section Abstract Doc Link 11758831 Disease Relevance 0.74 Pain Relevance 0.57

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox